Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data

Sai Nathan Ramnath; Parvathy V Nair; Melcy Mary Philip; Dhanya Sasidharan Palappallil

doi:10.5455/njppp.2023.13.07344202323072023

2023, Vol: 13, Issue: 9

13 / 9Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2023; 13(9): 1893-1897

doi: 10.5455/njppp.2023.13.07344202323072023

Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data

Sai Nathan Ramnath, Parvathy V Nair, Melcy Mary Philip, Dhanya Sasidharan Palappallil.

Abstract
Background: Pharmacovigilance is an important element of evidence-based medicine generating data for rational use of drugs.

Aims and Objectives: The aims and objectives of the study are to describe the pattern of adverse drug reactions (ADRs) reported to an ADR monitoring centre (AMC).

Materials and Methods: This was a retrospective analysis of ADRs reported to an AMC in South Kerala for a period of 3 years from October 2017 to September 2020 after obtaining Institutional Ethics Committee clearance. The data were entered in Excel and analyzed using SPSS 16.

Results: During the period under study, 634 ADRs were reported with a mean age of 48.75 ± 19.25 years. The most common organ affected was skin and appendages followed by the hepatobiliary system. The most common ADRs reported were itching, maculopapular rash, and elevated liver enzymes. Antimicrobials accounted for the maximum ADRs of which beta-lactams were the most common. The median time for occurrence of ADRs was after 4 days (interquartile range: 1.30). The majority of ADRs were probable, preventable, had moderate severity, and non-serious. Skin and integumentary followed by hepatobiliary system were the most common ADRs and isoniazid was the most common drug associated with ADRs.

Conclusion: Antimicrobials accounted for the maximum number of ADRs which were dominated by beta-lactams and antituberculosis drugs. Prospective studies on the development of ADRs will give better understanding of the temporality as well as outcome and management of ADRs.

Key words: Adverse Drug Reactions; Pharmacovigilance; Causality; Preventability; Temporality; Severity

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Sai Nathan Ramnath Articles by Parvathy V Nair Articles by Melcy Mary Philip Articles by Dhanya Sasidharan Palappallil
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Ramnath SN, Nair PV, Philip MM, Palappallil DS. Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. Natl J Physiol Pharm Pharmacol. 2023; 13(9): 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

Web Style

Ramnath SN, Nair PV, Philip MM, Palappallil DS. Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. https://www.njppp.com/?mno=160805 [Access: September 03, 2023]. doi:10.5455/njppp.2023.13.07344202323072023

AMA (American Medical Association) Style

Ramnath SN, Nair PV, Philip MM, Palappallil DS. Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. Natl J Physiol Pharm Pharmacol. 2023; 13(9): 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

Vancouver/ICMJE Style

Ramnath SN, Nair PV, Philip MM, Palappallil DS. Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. Natl J Physiol Pharm Pharmacol. (2023), [cited September 03, 2023]; 13(9): 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

Harvard Style

Ramnath, S. N., Nair, . P. V., Philip, . M. M. & Palappallil, . D. S. (2023) Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. Natl J Physiol Pharm Pharmacol, 13 (9), 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

Turabian Style

Ramnath, Sai Nathan, Parvathy V Nair, Melcy Mary Philip, and Dhanya Sasidharan Palappallil. 2023. Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. National Journal of Physiology, Pharmacy and Pharmacology, 13 (9), 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

Chicago Style

Ramnath, Sai Nathan, Parvathy V Nair, Melcy Mary Philip, and Dhanya Sasidharan Palappallil. "Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

MLA (The Modern Language Association) Style

Ramnath, Sai Nathan, Parvathy V Nair, Melcy Mary Philip, and Dhanya Sasidharan Palappallil. "Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data." National Journal of Physiology, Pharmacy and Pharmacology 13.9 (2023), 1893-1897. Print. doi:10.5455/njppp.2023.13.07344202323072023

APA (American Psychological Association) Style

Ramnath, S. N., Nair, . P. V., Philip, . M. M. & Palappallil, . D. S. (2023) Adverse drug reactions reported to an ADR monitoring centre as a part of the Pharmacovigilance Programme of India: A retrospective analysis of 3-year data. National Journal of Physiology, Pharmacy and Pharmacology, 13 (9), 1893-1897. doi:10.5455/njppp.2023.13.07344202323072023

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article